Clinical Report: Prolonged Severe Thrombocytopenia Following Ado-Trastuzumab Emtansine

Overview

This case study presents a 50-year-old woman who developed sustained grade 4 thrombocytopenia after adjuvant ado-trastuzumab emtansine (T-DM1) therapy. The thrombocytopenia was refractory to standard treatments but stabilized with romiplostim, highlighting the need for individualized management in such cases.

Background

Ado-trastuzumab emtansine (T-DM1) is a key treatment for HER2-positive early breast cancer, particularly after neoadjuvant therapy. Thrombocytopenia is a known side effect of T-DM1, with severe cases being uncommon and challenging to manage. Understanding the mechanisms and management strategies for this adverse effect is crucial for optimizing patient care.

Data Highlights

No numerical data or trial data was provided in the source material.

Key Findings

• A 50-year-old woman developed sustained grade 4 thrombocytopenia after three cycles of adjuvant T-DM1.
• Thrombocytopenia was refractory to recombinant human thrombopoietin and hetrombopag treatments.
• Sequential bone marrow evaluations indicated megakaryocytic maturation impairment.
• Romiplostim allowed for long-term stabilization of platelet counts.
• Further anti-HER2 therapy was withheld due to severely compromised thrombopoietic reserve.

Clinical Implications

This case emphasizes the importance of monitoring platelet counts in patients receiving T-DM1 and the potential role of romiplostim in managing severe thrombocytopenia. Clinicians should consider individualized treatment approaches for patients with refractory thrombocytopenia.

Conclusion

The occurrence of severe non-cyclic thrombocytopenia during HER2-directed ADC therapy necessitates careful evaluation and management. This case contributes to the understanding of thrombocytopenia in the context of T-DM1 treatment.

Related Resources & Content

1. NCCN Guidelines® Insights: Breast Cancer, Version 5.2025 - PubMed
2. Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1) | Clinical Cancer Research
3. the asco post — Romiplostim May Improve Chemotherapy-Induced Thrombocytopenia in Patients With GI Cancers
4. The ASCO Post — Romiplostim May Improve Chemotherapy-Induced Thrombocytopenia in Patients With GI Cancers
5. The ASCO Post — Romiplostim Improves Chemotherapy-Induced Thrombocytopenia in GI Cancers
6. Frontiers in Medicine — Rapid early hematological response in a newly diagnosed patient with very severe aplastic anemia: a case report of high-dose romiplostim, hetrombopag and IST combination therapy
7. Romiplostim May Improve Chemotherapy-Induced Thrombocytopenia in Patients With GI Cancers
8. NCCN Guidelines® Insights: Breast Cancer, Version 5.2025 - PubMed
9. label
10. Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1) | Clinical Cancer Research | American Association for Cancer Research